Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
A predawn landslide triggered by torrential rains on Indonesia’s main island of Java has killed at least eight people and ...
While standard models suffer from context rot as data grows, MIT’s new Recursive Language Model (RLM) framework treats ...
For decades, artificial intelligence advanced in careful, mostly linear steps. Researchers built models. Engineers improved performance. Organizations deployed systems to automate specific tasks. Each ...
Recursion Pharmaceuticals' (NASDAQ: RXRX) stock price has seen a dramatic increase, not due to company-specific news or drug announcements, but rather due to actions taken by artificial intelligence ...
New Rust release brings major improvements to musl’s DNS resolver and tweaks the standard library to aid global allocators.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results